[This Week's IPO] Demand Forecast and Subscription Schedule for the First Week of January

[Asia Economy Reporter Jang Hyowon] In the first week of this month (January), Auto& (Auto And), K-Auction, and Adbiotech will conduct demand forecasting for institutional investors.

◆Auto&= Auto&, started in 2008 as an in-house venture of Hyundai Motor Group, spun off in 2012. Established with the motto of being Korea's first automobile specialized platform company, Auto& has built a sourcing network of about 20,000 vehicle accessories and an offline installation point network of about 10,000, gaining recognition for its competitiveness.

The total number of shares offered is 2,877,579, with a public offering price band of 4,200 to 4,800 KRW. The expected amount to be raised is approximately 12.1 billion to 13.8 billion KRW, and the expected market capitalization after the offering is about 54.1 billion to 61.8 billion KRW. The demand forecasting for institutional investors, delayed due to amendments to the securities registration statement, is scheduled to take place on the 5th and 6th. The lead underwriters are Mirae Asset Securities and Hyundai Motor Securities.

◆K-Auction= Established in 2005, K-Auction operates in art auction, sales, and brokerage. In 2006, it launched the industry's first online auction. As of the first half of this year, it holds a 42% market share in the domestic art auction market and conducts stable and systematic auctions based on the art management platform 'K-Office.'

The total shares offered this time are 1.6 million. The public offering price band is 17,000 to 20,000 KRW, with a total offering amount of 27.2 billion to 32 billion KRW. The expected market capitalization is 151.5 billion to 178.2 billion KRW. After demand forecasting for institutional investors on the 6th and 7th, the public offering price will be finalized, followed by general subscription on the 12th and 13th. The lead underwriter is Shin Young Securities.

◆Adbiotech= Adbiotech, a KONEX-listed company, is an immunoantibody bio company developing and selling antibody pharmaceuticals using high-titer antibodies (specific egg yolk antibodies) produced from eggs. The antibody pharmaceuticals, which received high evaluations in technology assessment, are capable of disease prevention and treatment and are described as a highly scalable technology applicable to livestock, fisheries, and humans, recognized both domestically and internationally.

The total number of shares offered is 1.36 million, with a public offering price band of 7,000 to 8,000 KRW, aiming to raise 9.5 billion to 10.9 billion KRW. Demand forecasting for institutional investors is scheduled for the 6th and 7th. The lead underwriter is Daishin Securities.

This content was produced with the assistance of AI translation services.